Physician profile
Devon Cohen
NPI 1508229428
$1,913.81
in general payments reported to CMS, 2019-2025
25 companies · $62.47 in 2025
The $62.47 reported for 2025 was less than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $695 · 2023: $19.56 · 2024: $187 · 2025: $62.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $384.24 | 2021 | |
| Amgen INC. | $205.51 | 2021-2024 | Uplizna |
| Abbvie INC. | $205.33 | 2021-2024 | Botox |
| Biogen, INC. | $116.51 | 2021-2022 | |
| Lilly USA, LLC | $99.10 | 2021-2022 | |
| Genzyme Corporation | $79.11 | 2021-2022 | |
| Sk Life Science, INC. | $78.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $74.12 | 2021-2022 | |
| Allergan, INC. | $67.35 | 2022 | |
| Lundbeck LLC | $66.13 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $62.47 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $56.20 | 2021-2022 | |
| Eisai INC. | $55.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.50 | 2021-2022 | |
| Emd Serono, INC. | $47.68 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $46.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $45.39 | 2021-2022 | |
| Banner Life Sciences, LLC | $32.77 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.95 | 2022 | |
| Mdd US Operations, LLC | $22.69 | 2021 | |
| Octapharma USA, INC. | $21.45 | 2021 | |
| Alfasigma USA, INC. | $21.28 | 2021 | |
| Kyowa Kirin, INC. | $19.67 | 2021 | |
| Impel Pharmaceuticals INC. | $19.45 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.